Single treatment with γ-T3, PPARγ agonists (rosiglitazone or troglitazone) or antagonists (GW9662 or T0070907) resulted in a dose-dependent growth inhibition of breast cancer cells. The gene discussed is PPARG; the disease is breast cancer.